January 26, 2011

Margaret Hamburg, M.D.
Commissioner
Food and Drug Administration
Department of Health and Human Services
10903 New Hampshire Avenue
Silver Spring, MD 20993

Monica Knoll
Executive Director / Founder / Survivor
CANCER101 Inc.
a 501(C)3 nonprofit organization
Donations/Billing: 429 East 52nd Street, Suite 25D, NY, NY 10022
Office/Packages: 263 West 38th Street, 16th floor, NY, NY 10018
T.646.638.2202 **F.**646.349.3035
Mknoll@CANCER101.org www.CANCER101.org

Dear Dr. Hamburg:

CANCER101 is a national nonprofit that helps cancer patients and their caregivers to get organized and informed to fight their cancer. Although we do not provide treatment recommendations, we do help direct patients towards access to care.

I am writing to you today to share my deep concern about the FDA's decision to withdraw approval of Avastin (bevacizumab) as a treatment option for metastatic breast cancer patients.

I am a ten year breast cancer survivor and currently being treated for my third bout of ovarian cancer. I have been fortunate to receive Avastin for my ovarian cancer treatment and I am enjoying benefit from this drug.

It is my hope that the FDA grants Genentech a fair hearing and ultimately gives metastatic breast cancer patients the option to receive the same benefits I am currently receiving from Avastin.

It is vital that patients have as many treatment options as possible. Many metastatic breast cancer patients have and are, currently responding to Avastin. Please do not take away this option or insurance coverage from them or future patients.

Healthy wishes,

Monica Knoll

Executive Director/Founder/Four-time cancer survivor